dc.contributor.author |
Sathekge, Mike Machaba
|
|
dc.contributor.author |
Lengana, Thabo
|
|
dc.contributor.author |
Modiselle, Moshe
|
|
dc.contributor.author |
Vorster, Mariza
|
|
dc.contributor.author |
Zeevaart, Jan Rijn
|
|
dc.contributor.author |
Maes, Alex
|
|
dc.contributor.author |
Ebenhan, Thomas
|
|
dc.contributor.author |
Van de Wiele, Christophe
|
|
dc.date.accessioned |
2018-01-12T06:42:49Z |
|
dc.date.available |
2018-01-12T06:42:49Z |
|
dc.date.issued |
2017-04 |
|
dc.description.abstract |
BACKGROUND : To report on imaging findings using 68Ga-PSMAHBED-
CC PET in a series of 19 breast carcinoma patients.
METHODS : 68Ga-PSMA-HBED-CC PET imaging results obtained
were compared to routinely performed staging examinations
and analyzed as to lesion location and progesterone
receptor status.
RESULTS : Out of 81 tumor lesions identified, 84% were identified
on 68Ga-PSMA-HBED-CC PET. 68Ga-PSMA-HBED-CC
SUVmean values of distant metastases proved significantly
higher (mean, 6.86, SD, 5.68) when compared to those of primary
or local recurrences (mean, 2.45, SD, 2.55, p = 0.04) or
involved lymph nodes (mean, 3.18, SD, 1.79, p = 0.011).
SUVmean values of progesterone receptor-positive lesions
proved not significantly different from progesterone receptornegative
lesions. SUV values derived from FDG PET/CT, available
in seven patients, and 68Ga-PSMA-HBED-CC PET/CT
imaging proved weakly correlated (r = 0.407, p= 0.015).
CONCLUSIONS : 68Ga-PSMA-HBED-CC PET/CT imaging in
breast carcinoma confirms the reported considerable variation
of PSMA expression on human solid tumors using
immunohistochemistry. |
en_ZA |
dc.description.department |
Nuclear Medicine |
en_ZA |
dc.description.librarian |
am2018 |
en_ZA |
dc.description.sponsorship |
Department of Nuclear Medicine at University
Pretoria and NECSA. |
en_ZA |
dc.description.uri |
https://link.springer.com/journal/259 |
en_ZA |
dc.identifier.citation |
Sathekge, M., Lengana, T., Modiselle, M. et al. 68Ga-PSMA-HBED-CC PET imaging in breast carcinoma patients. European Journal of Nuclear Medicine and Molecular Imaging (2017) 44: 689-694. https://doi.org/10.1007/s00259-016-3563-6. |
en_ZA |
dc.identifier.issn |
1619-7070 (print) |
|
dc.identifier.issn |
1619-7089 (online) |
|
dc.identifier.other |
10.1007/s00259-016-3563-6 |
|
dc.identifier.uri |
http://hdl.handle.net/2263/63510 |
|
dc.language.iso |
en |
en_ZA |
dc.publisher |
Springer |
en_ZA |
dc.rights |
© The Author(s) 2016. This article is published with open access at Springerlink.com. This article is distributed under the terms of the Creative
Commons Attribution 4.0 International License (http://
creativecommons.org/licenses/by/4.0/). |
en_ZA |
dc.subject |
68Ga-PSMA |
en_ZA |
dc.subject |
PET/CT |
en_ZA |
dc.subject |
Breast cancer |
en_ZA |
dc.subject |
Prostate-specific membrane antigen (PSMA) |
en_ZA |
dc.subject |
Positron emission tomography (PET) |
en_ZA |
dc.title |
68Ga-PSMA-HBED-CC PET imaging in breast carcinoma patients |
en_ZA |
dc.type |
Article |
en_ZA |